Claims
- 1. A topical composition comprising an agent selected from the group consisting of inhibitors of ceramide synthesis, acylceramide synthesis, glucosylceramide synthesis, sphingomyelin synthesis, fatty acid synthesis, and cholesterol synthesis; inhibitors of phospholipid, glycosphingolipid, acylceramide and sphingomyelin degradation; degradation enzymes of free fatty acid, ceramide, sphingomyelin, acylceramide, and glucosylceramides; and both inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol, together with a pharmaceutically acceptable carrier, wherein the agent is present at a concentration of about 0.01% to about 5.0% by weight of said composition.
- 2. A topical composition according to claim 1 wherein the agent is an inhibitor of HMG CoA reductase.
- 3. A topical composition according to claim 2 wherein the inhibitor of HMG CoA reductase is a member selected from the group consisting of simvastatin, lovastatin, fluindostatin, pravastatin, mevastatin, cholesterol sulfate, cholesterol phosphate, and oxygenated sterols.
- 4. A topical composition according to claim 2 wherein the inhibitor of HMG CoA reductase is a member selected from the group consisting of simvastatin, lovastatin, fluindostatin, pravastatin, and mevastatin.
- 5. A topical composition according to claim 2 wherein the inhibitor of HMG CoA reductase is mevastatin.
- 6. A topical composition according to claim 2 wherein the inhibitor of HMG CoA reductase is an oxygenated sterol.
- 7. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of inhibitors of serine palmitoyl transferase, inhibitors of ceramide synthetase, inhibitors of sphingomyelinase, inhibitors of β-glucosidase, inhibitors of acid lipase, inhibitors of α-hydroxylation, inhibitors of N-acyl chain length elongation, inhibitors of ω-acyl transferases, inhibitors of glucosyl transferase, and inhibitors of phosphatidylcholine-ceramide phosphatidylcholine transferase.
- 8. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of β-chloroalanine, fluoropalmitate, and β-fluoroalanine.
- 9. A topical composition according to claim 1 wherein the agent is fumonisins.
- 10. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of tricyclodecan-9-yl-xanthogenate, ethylisopropylamiloride, N-palmitoyl-DL-dihydroxysphingosine, and methylene-dioxybenzapine.
- 11. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of N-hexylglucosyl-sphingosine, bromoconduritol-β-epoxide, conduritol, cyclophellitol, conduritol-β-epoxide, and deoxynojirimycin.
- 12. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of boronic acid, phenylboronic acid, tetrahydrolipstatin, and esterasin.
- 13. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of 1-phenyl-2-decanolamino-3-morpholino-1-propanol and its analogs.
- 14. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of 1-phenyl-2-decanolarmine-3-morpholine-1-propanol, p-nitro-phenyl-α-xyloside, 4-methyl umbelliferyl-β-O-xyloside, and o- and p-nitrophenyl-β-O-xyloparanoside.
- 15. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of inhibitors of acetyl CoA carboxylase, inhibitors of fatty acid synthetase, and inhibitors of phospholipase.
- 16. A topical composition according to claim 1 wherein the agent is 5-tetradecyloxy-2-furancarboxylic acid.
- 17. A topical composition according to claim 1 wherein the agent is gomisin A.
- 18. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of 2-(p-amylcinnamyl) amino-4-chlorobenzoic acid, bromophenacylbromide, 7,7-dimethyl-5,8-eicosadienoic acid, dibutyryl-cyclic AMP, diaminoethoxylhexesterol, N-oleoylethanolamine, and N-(7-nitro-2,1,3-benzoxadiazol-4-yl) phosphatidylserine.
- 19. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of inhibitors of phospholipid degradation, glycosphingolipid degradation, acylceramide degradation, and sphingomyelin degradation.
- 20. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of bromoconduritol-β-epoxide, conduritol-β-epoxide, and cyclophellitol.
- 21. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of degradation enzymes of free fatty acid, ceramide, sphingomyelin, acylceramide, or glucosylceramide.
- 22. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of ceramidase, sphingomyelinase, acid lipase, and β-glucosidase.
- 23. A topical composition according to claim 1 wherein the agent is a member selected from the group consisting of inhibitors and stimulators of metabolic enzymes of free fatty acids, ceramide, and cholesterol.
Parent Case Info
This application is a continuation of application Ser. No. 09/058,401, filed Apr. 9, 1998, U.S. Pat. No. 6,190,894, which is a conitinuation of application Ser. No. 08/733,712, filed Oct. 23, 1996, now abandoned, which is a continuation-in-part of application Ser. No. 08/260,559, filed Jun. 16, 1994, now abandoned, which is a continuation-in-part of application Ser. No. 08/033,811, filed Mar. 19, 1993, now abandoned. All of the applications cited in this paragraph are incorporated herein by reference.
GOVERNMENT RIGHTS
This invention was made with Government support by The Department of Veterans Affairs. The Government may therefore have certain rights in this invention.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
4420474 |
Sykes |
Dec 1983 |
A |
4946670 |
Sebag et al. |
Aug 1990 |
A |
5120545 |
Ledger et al. |
Jun 1992 |
A |
5130139 |
Cormier et al. |
Jul 1992 |
A |
6190894 |
Thornfeldt et al. |
Feb 2001 |
B1 |
Foreign Referenced Citations (4)
Number |
Date |
Country |
3325506 |
Jan 1985 |
DE |
1051461 |
Dec 1966 |
GB |
1070593 |
Jun 1967 |
GB |
03153634 |
Jan 1991 |
JP |
Non-Patent Literature Citations (4)
Entry |
American Pharmaceutical Association, “Handbook of Pharmaceutical Excipients”, American Pharmaceutical Association (Washington D.C.), pp. 1242-1243. |
Budavari, et al. “The Merck Index” published by Merck & Co., Inc. (New Jersey), p. 208. |
Fransson, et al. “Effects of Cycloheximide, Brefeldin A, Suramin, Heparin and Primaquine on Proteoglycan and Glycosaminoglycan Biosynthesis in Human Embryonic Skin Fibroblasts” Biochimica et Biophysica Acta (1992) vol. 1137, pp. 287-297. |
Gennaro, et al. “Remington's Pharmaceutical Sciences” published by Mack (Pennsylvania), pp. 1242-1243. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/058401 |
Apr 1998 |
US |
Child |
09/608568 |
|
US |
Parent |
08/733712 |
Oct 1996 |
US |
Child |
09/058401 |
|
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08/260559 |
Jun 1994 |
US |
Child |
08/733712 |
|
US |
Parent |
08/033811 |
Mar 1993 |
US |
Child |
08/260559 |
|
US |